Mexico City to build world-class hub for medical research

4 December 2009

The government of Mexico City says it will build a world-class center for biomedical and nanomedical research, called Campus Biometropolis. The center for medical R&D will be integrated with the National Autonomous University of Mexico, claimed to be the top Spanish speaking university in the world.

Campus Biometropolis, which is expected attract significant investment over the next several years, will become an engine for the transformation of Mexico's economy. Mexico has first-class human resources and considerable infrastructure to position itself as the leading knowledge center for Latin America, according to a press statement.

This state-of-the-art R&D cluster will look to attract pharmaceutical and biomedical companies and organizations from around the world. Given its close proximity to corporate laboratories, start-ups and public research institutions, it will provide fertile ground for R&D, and offer an environment to accelerate product development and commercialization.

"Mexico City's Campus Biometropolis is the cornerstone of a broader vision to transform Mexico City into a knowledge capital," said Mexico City Mayor Marcelo Ebrard, adding: "This is a critical investment in the future of Mexico City, taking us a step further toward becoming a global hub of scientific and technological excellence."

Campus Biometropolis will be sustainably designed and built, and will be composed of hospitals, laboratories and medical universities, as well as residential and retail areas. In addition, the complex will include a natural reserve and will become a model for green buildings and water conservation. This project is in accordance with Mayor Ebrard's plan to transform the city into one of the most environmentally-conscience and sustainable cities in the world.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical